The U.S. NIH awarded $87 million to establish the Standardized Organoid Modeling Center aiming to develop reproducible protocols for organoid research, elevating its role in drug discovery and reducing reliance on animal testing. This initiative aligns with FDA’s regenerative medicine pathway guidance and advances biopharma’s transition towards human-relevant models for efficacy and toxicity screening, with broad implications for accelerating therapeutic development.